We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Verona Pharma plc (VRNA) ADR EACH REP 8 ORD SHS SPON

Sell:$37.28 Buy:$37.65 Change: $0.99 (2.55%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$37.28
Buy:$37.65
Change: $0.99 (2.55%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$37.28
Buy:$37.65
Change: $0.99 (2.55%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.

Contact details

Address:
Riverside, 3 More London Place
LONDON
SE1 2RE
United Kingdom
Telephone:
+44 (20) 32834200
Website:
https://www.veronapharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VRNA
ISIN:
US9250501064
Market cap:
$3.18 billion
Shares in issue:
648.65 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
Great Britain
Currency:
US dollar
Indices:
n/a

Key personnel

  • David Zaccardelli
    President, Chief Executive Officer, Executive Director
  • Mark Hahn
    Chief Financial Officer
  • Claire Poll
    General Counsel
  • Kathleen Rickard
    Chief Medical Officer
  • Ben Harber
    Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.